Opinion
Video
Maximizing Time on Therapy to Preserve Future Treatment Options in EGFR-Mutated NSCLC
Panelists discuss how medical professionals balance maximizing progression-free survival with preserving future treatment options by considering disease biology, resistance mechanisms, and patient factors. At first progression, the NCCN recommends continuing current therapy or switching to amivantamab with a platinum doublet, based on mutation status, prior response, toxicity, and patient preferences.
Video content above is prompted by the following:
- How do you weigh the benefits of selecting therapies that maximize progression-free survival against the importance of preserving future treatment options?
- At first progression, NCCN recommends either continuing the patient’s current systemic therapy or changing therapy to amivantamab combined with a platinum doublet. What are the most important clinical factors to consider when making this decision?
Latest CME
View All
Video
Community Oncology Connections™: Case Discussions in TNBC…Navigating the Latest Advances and Impact of Disparities in Care | North Carolina
Apr 17th 2025 - May 23rd 2025
online-activity
Video
Community Oncology Connections™: Community Oncologists’ Role in Selecting Optimal Oral SERD Treatment for HR+/HER2– Breast Cancer | Minnesota
Apr 17th 2025 - May 23rd 2025
online-activity
Video
18th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies
Apr 8th 2025 - May 14th 2025
online-activity
Related Content
.png?fit=crop&auto=format)
.jpg?fit=crop&auto=format)
